Phio Pharmaceuticals (PHIO) said Wednesday the Safety Monitoring Committee has recommended dose escalation in its phase 1b clinical trial of PH-762 as a potential neoadjuvant treatment for cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.
The recommendation came after seven patients in the study with cutaneous carcinoma showed at least 90% tumor clearance after 36 days, the company said.
Shares of the biotech firm were up more than 20% in recent premarket activity Wednesday.
Price: 1.22, Change: +0.21, Percent Change: +20.76
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.